Daraxonrasib pancreatic cancer treatment has taken a new step forward. New first-line trial data presented on Friday 20 November 2026 shows the once-daily pill, combined with chemotherapy, shrank tumours in 60.7% of patients with metastatic pancreatic cancer who had never been treated before — and in 8.2% of them, about one patient in twelve, tumours disappeared entirely on scans. The results, presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, are trending per news coverage as the latest chapter for a drug that only won approval in the United States in August.

Pancreatic cancer is one of the most difficult cancers to treat, and most cases are found after the disease has already spread. For decades, chemotherapy infusions have been the standard first treatment, and second-line options have barely changed in years. The daraxonrasib pancreatic cancer pill is different: it targets the RAS proteins driving most pancreatic cancers, and the new data is the first sign it may work even better when given earlier, alongside chemotherapy, than it did on its own.

What the New Daraxonrasib Pancreatic Cancer Trial Found

The new results come from the RMC-GI-102 trial, a phase I/II study testing daraxonrasib together with two standard chemotherapy drugs, gemcitabine and nab-paclitaxel, in patients whose pancreatic cancer had spread and who had not previously received treatment for metastatic disease. Patients took 200 mg of daraxonrasib by mouth once a day, with the chemotherapy drugs given by intravenous injection on days 1 and 15 of each treatment cycle.

As of the 28 September 2026 data cutoff, 61 patients had received the combination, with a median follow-up of 18.3 months. Tumours shrank or disappeared in 60.7% of patients. That included complete responses in 8.2% — five of the 61 patients — in whom tumours were no longer detectable. Tumours stopped growing in 90.2% of patients, and the median time before tumours returned or started growing again was 12.8 months. The estimated 12-month overall survival rate was 76.6%, according to the trial update reported by ecancer and OncLive.

"By combining daraxonrasib with chemotherapy, we are seeing remarkably deep tumour responses in a substantial proportion of patients, together with durable disease control, with a median progression-free survival exceeding one year," said Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York and the study's principal investigator. He added that the 12-month survival figure "provides further insight into the sustained clinical benefit" of the combination.

The new numbers build on earlier data from the same trial, first presented at the 2026 AACR Annual Meeting, when 40 patients had achieved a 58% response rate and 90% disease control. The combination is now being compared with gemcitabine and nab-paclitaxel alone in a phase 3 trial, RASolute 303.

Daraxonrasib Pancreatic Cancer: How the Pill Blocks RAS

Daraxonrasib works by blocking RAS, a family of proteins that act as on-off switches for cell growth. In pancreatic cancer, mutations in the KRAS gene leave that switch stuck in the "on" position, telling cells to keep growing and dividing. About 90% of pancreatic cancers carry a KRAS mutation, according to Duke Health, which is why RAS has been called one of the most important drivers of the disease — and one of the hardest to drug.

The pill, developed by Revolution Medicines under the code name RMC-6236 and sold as Rasonque, binds first to a protein called cyclophilin A inside the cell and then to the RAS protein itself, forming a barrier that stops the growth signals from reaching their targets. Unlike earlier KRAS drugs, which worked only against a single mutation variant, daraxonrasib is designed to block RAS across many variants, including the most common ones in pancreatic cancer, KRAS G12D and G12V. AI detection tools are also spotting pancreatic cancer months earlier, but daraxonrasib is the first treatment to attack the RAS driver itself with a daily pill.

Daraxonrasib vs Chemotherapy: The Trial Behind the Approval

The daraxonrasib pancreatic cancer evidence rests on a larger, separate trial. RASolute 302, a phase 3 study published in the New England Journal of Medicine, enrolled 500 patients with previously treated metastatic pancreatic cancer across 59 sites in six countries. Patients were randomised one-to-one to receive daraxonrasib at 300 mg once daily or the investigator's choice of chemotherapy.

Patients taking daraxonrasib lived a median of 13.2 months, compared with 6.6 months for those on chemotherapy in the RAS G12 population, and 13.2 months versus 6.7 months in the overall population — nearly doubling survival, and cutting the risk of death by 60%. The time before the cancer grew was 7.3 months versus 3.5 months, and tumours shrank in 33.2% of patients on the drug compared with 11.8% on chemotherapy. Patients on daraxonrasib also reported feeling better for longer: the time to pain deterioration was 9.0 months versus 3.7 months.

"The results of RASolute 302 are immediately practice-changing in pancreatic cancer and define a precision medicine approach for nearly every patient with this disease," said Dr Eileen M. O'Reilly of Memorial Sloan Kettering Cancer Center, a co-lead author of the study alongside Dr Zev A. Wainberg of UCLA and Dr Brian M. Wolpin of Dana-Farber Cancer Institute.

On 26 August 2026, the US Food and Drug Administration approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have already had at least one other treatment, or who cannot take combination chemotherapy. The European Commission has also approved it. It is the first RAS-directed therapy to receive regulatory approval for pancreatic cancer, and the approval carries no restriction by KRAS mutation status — wider than investigators had expected.

Side Effects and the $39,800-a-Month Price Tag

Daraxonrasib is not a cure, and its side effects need close monitoring. In the RASolute 302 trial, the most common problems were rash, affecting 86.3% of patients, diarrhoea in 67.2%, and mouth sores in 54.8%. Most were mild or moderate, and severe side effects were actually less frequent with daraxonrasib than with chemotherapy — 61.8% versus 69.6%. One death from treatment-related lung inflammation was reported in the daraxonrasib group.

In the first-line combination trial, the side effects were similar — rash, diarrhoea, fatigue, and the low blood counts that come with chemotherapy — and only 5% of patients stopped treatment because of daraxonrasib-related side effects. Doctors say the rash and diarrhoea need to be watched by an experienced team, and patients on the pill still need regular lab tests and clinic visits. The FDA is also investigating safety signals for other new medicines, which is a reminder that new drugs keep being watched after approval.

Then there is the price. Revolution Medicines set a list price of $39,800 a month — about $478,000 for a year of treatment — though most of that is expected to be covered by insurance, according to the New York Times. The company runs a patient-support programme to help with insurance navigation and financial assistance, and the drug is already available in the US through an early access programme.

What Happens Next for Daraxonrasib

Two more daraxonrasib pancreatic cancer trials are already running. RASolute 303 is testing daraxonrasib plus chemotherapy against chemotherapy alone as a first treatment for metastatic disease — the head-to-head test that will decide whether the combination becomes a new standard. RASolute 304 is testing the drug against observation after surgery, to see whether it can stop pancreatic cancer coming back in patients whose tumours have been removed. Researchers are also studying the pill in other cancers driven by RAS mutations.

For patients and families, the practical point is narrower than the headlines. The drug is approved now only for metastatic pancreatic cancer after earlier treatment, or for people who cannot take combination chemotherapy. The first-line combination data is promising, but it comes from a small, early-stage trial of 61 patients, and it has not yet been tested against chemotherapy alone. Targeted therapies are producing striking results elsewhere too, yet each one still has to clear the same bar: a randomised trial showing it beats the standard treatment.

Anyone considering the daraxonrasib pancreatic cancer pill should talk to their oncologist about whether they qualify, what the side effects would mean day to day, and what their insurance will cover. The next milestone to watch is the RASolute 303 result — if the combination beats chemotherapy alone in a randomised trial, a pill that patients take at home could move to the front of pancreatic cancer treatment for the first time.